69422-73-7

Usage

Use

as a key building block in the synthesis of various pharmaceuticals and agrochemicals.

Derivative

of nicotinoyl chloride, which is known for its antitumor and anti-inflammatory properties.

Reactivity

Highly reactive, primarily used in organic synthesis and chemical research.

Safety

corrosive and can cause skin and eye irritation upon contact, should be handle with care.

Upstream product

• 69422-72-6 2,4,6-trichloronicotinoic acid 
• 2402-78-0 2,6-dichloropyridine 
• 2587-00-0 2,6-dichloropyridine N-oxide 
• 16063-69-7 2,4,6-trichloropyridine 

Downstream Products

• 1391001-28-7 tert-butyl 4-(4-(7-chloro-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-5-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390655-18-1 8-(2,6-dichlorobenzyl)-6-(4-(piperazin-1-yl)phenylamino)-1,2,3,4-tetrahydropyrido[4,3-e][1,4]diazepin-5-one 
• 1390656-61-7 tert-butyl 4-(4-(8-chloro-5-oxo-2,3,4,5-tetrahydro-1H-pyrido[4,3-e][1,4]diazepin-6-ylamino)phenyl)piperazine-1-carboxylate 
• 1390655-15-8 8-(2,6-dichlorobenzyl)-6-{[4-(piperazin-1-yl)phenyl]amino}-1,2,3,4-tetrahydro-5H-pyrido[2,3-e][1,4]diazepin-5-one 
• 1390656-57-1 tert-butyl 4-(4-(8-chloro-5-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-6-ylamino)phenyl)piperazine-1-carboxylate 
• 1390655-14-7 8-(2,6-dichlorobenzyl)-6-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}-1,2,3,4-tetrahydro-5H-pyrido[2,3-e][1,4]diazepin-5-one 
• 1390656-56-0 tert-butyl 4-(4-(8-chloro-5-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-6-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 

Relevant academic research and scientific papers

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

BICYCLIC INHIBITORS OF ALK

The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, Formula (1) wherein R1, R2, R3, X, Y, Z, A, B, G1, m, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

BICYCLIC INHIBITORS OF ALK

The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

Synthesis and Structure-Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 2

We have previously reported that a series of 7-substituted 6-fluoro-1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids possess moderate cytotoxic activity. In a further attempt to find clinically useful antitumor agents, we investigated the structure-activity relationships (SARs) of a new series of compounds obtained by changing the C-6 position of the fluorine atom in addition to the C-5 and C-7 positions and evaluating their cytotoxic activity against several murine and human tumor cell lines. Our results showed that the 6-unsubstituted 1,8-naphthyridine structure had the most potent cytotoxic activity against murine P388 leukemia twice that of the 6-fluoro analogue. In addition, introduction of an amino group at the C-5 position did not have any substantial effect on the cytotoxic activity, while both the 5-chloro and 5-trifluoromethyl groups decreased the cytotoxic activity by 5- to 10-fold. Moreover, aminopyrrolidine derivatives at the C-7 position showed more potent cytotoxic activity than other amines or carbon derivatives. Among the 7-(3-aminopyrrolidinyl) derivatives, the trans-3-methoxy-4-methylaminopyrrolidinyl derivative (271) was determined to have potent cytotoxic activity in both in vitro and in vivo assays and high water solubility. Finally, the (S,S)-isomer (AG-7352, 3) of 271, with a cytotoxic activity against human tumor cell lines more potent than that of etoposide, was selected for further development.